5,310 research outputs found
Physiopathology and Treatment of Obesity and Overweight: A Proposal for a New Anorectic
No full textThe "new epidemic,"as WHO calls obesity, is caused by overeating, which, having exceeded the body's actual needs, accumulates in the form of health-damaging fat deposits. Moving more and eating less is the main remedy, but eating belongs to vital instincts, which are beyond the control of reason. In this sense, eating is different from drinking and breathing because without food it is possible to survive for a few weeks, without water for a few days, without oxygen for a few minutes. The first part of this article provides an overview of obesity and its treatment, focusing on the new anorectic anticipated in the title. The second part focuses on compulsive obesity, typically represented by constitutional obesity and food addiction. The article concludes with a discussion of the pharmacological treatment of compulsive diseases, to which some forms of obesity belong
Antidenaturant drugs for cataract and other condensation diseases
No full text'Condensation diseases' are heterogeneous pathological conditions in which the primary pathogenetic step is the loss of solubility of specific substances, resulting in the formation of a condensed phase. Typical examples are cataract, nephrolithiasis, gallstone disease and certain rheumatic conditions in which protein denaturation, aggregation and precipitation may occur. Since the condensing molecules are often proteins, antidenaturant agents should be considered rational drugs for the treatment of these diseases. Surprisingly, however, only a few molecules with these properties are currently available for therapeutic use, including bendazac for cataract
Effects of D-lysergic acid diethylamine on serotonin, adrenaline and dopamine evoked aorta contractions.
No full textBINDING PROFILE OF TRAZODONE AND DAPIPRAZOLE TO SOME BRAIN RECEPTORS
No full textTrazodone and dapiprazole displace ligands binding to rat brain alpha-1 adrenoceptors. The displacement of 3H-ligands to alpha-2, serotonin1 (5-HT1), dopamine, beta and opiate receptors is either absent or takes place at relatively higher concentrations. Trazodone, unlike dapiprazole, also inhibits binding to serotonin2 (5-HT2) receptors. Some pharmacological effects show a satisfactory correlation with these data. The psychopharmacological effects of trazodone and dapiprazole are similar, whereas the binding inhibition to 5-HT2 receptors is different, which could indicate that the psychopharmacological effects do not primarily depend on these receptors. The displacement of the binding to alpha-1 adrenoceptors by dapiprazole has a time course similar to that of its brain concentrations as well as to that of sedative and alpha-blocking effects. Dapiprazole and trazodone have antinociceptive effects and inhibit the binding to opiate receptors, although at relatively high concentrations
Coscienza civile individuale e bene comune. Per la riscoperta del valore dell’educazione
No full text- …
